Novel Epigenomic Liquid Biopsy Assay Predict Estrogen Recepr (ER) Status and Infer ER Pathway Activation in Breast Cancer

Classification of HER2 Status Across Multiple Cancers Using Epigenomic Profiles from A Novel Liquid Biopsy Assay

Presents Poster at 21st Annual Meeting of Association of Cancer Immunorapy (CIMT) in Mainz, Germany

Chief Executive Officer Ivan Cheung Named 2024 Time100 Health List

Novel Liquid Biopsy-based Determination of Lung Cancer Histology Using a Comprehensive Epigenomic Platform Reveals Enhancer Activity as A Key Determinant for Accurate Classification

Data Presented at AACR 2024 Precede Biosciences’ Power Impact Precision Medicine from a Simple Blood Test

A Novel Epigenomic Profiling Assay Reveals Disease Biology and Therapeutic Targets in Gastro-esophageal Cancer from 1mL of Plasma

Comprehensive Epigenomic Profiling from Plasma Inform Therapy Selection: A Proof-of-Concept Study in Cancer

Precede Biosciences Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024

Gordon J. Freeman, PhD, FAACR, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology I AACR I News Releases

First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

Closing of Series B Financing Extension Led by Catalio Capital Management

Appoints Ivan Cheung as Chief Executive Officer

Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer

IND Clearance from FDA Advance NPX887, a Novel Therapeutic Targeting HHLA2 Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

2023 SABCS Presentation: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform H